These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 26630704)

  • 1. Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.
    Mar N; Vredenburgh JJ
    Conn Med; 2015 Oct; 79(9):531-5. PubMed ID: 26630704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting HER2 in the treatment of non-small cell lung cancer.
    Mar N; Vredenburgh JJ; Wasser JS
    Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer.
    Kuyama S; Hotta K; Tabata M; Segawa Y; Fujiwara Y; Takigawa N; Kiura K; Ueoka H; Eguchi K; Tanimoto M
    J Thorac Oncol; 2008 May; 3(5):477-82. PubMed ID: 18448999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 and lung cancer.
    Landi L; Cappuzzo F
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1219-28. PubMed ID: 24134423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
    J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
    Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
    J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
    Dongiovanni D; Daniele L; Barone C; Dongiovanni V; Fissore C; Sapino A; Macrì L; Bussolati G; Buffoni L; Gaspari F; Grillo R; Birocco N; Addeo A; Ciuffreda L; Schena M
    Lung Cancer; 2008 Jul; 61(1):73-81. PubMed ID: 18243402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The force of HER2 - A druggable target in NSCLC?
    Jebbink M; de Langen AJ; Boelens MC; Monkhorst K; Smit EF
    Cancer Treat Rev; 2020 Jun; 86():101996. PubMed ID: 32135383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer.
    Wulf MA; Bode B; Zimmermann D; Rufibach K; Weder W; Moch H; Soltermann A; Tischler V
    Am J Surg Pathol; 2012 Dec; 36(12):1801-8. PubMed ID: 23154768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.
    Heinmöller P; Gross C; Beyser K; Schmidtgen C; Maass G; Pedrocchi M; Rüschoff J
    Clin Cancer Res; 2003 Nov; 9(14):5238-43. PubMed ID: 14614004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
    Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
    Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of HER2 overexpression in non-small cell lung cancer.
    Ugocsai K; Mándoky L; Tiszlavicz L; Molnár J
    Anticancer Res; 2005; 25(4):3061-6. PubMed ID: 16080566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
    Junker K; Stachetzki U; Rademacher D; Linder A; Macha HN; Heinecke A; Müller KM; Thomas M
    Lung Cancer; 2005 Apr; 48(1):59-67. PubMed ID: 15777971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.
    Cappuzzo F; Bemis L; Varella-Garcia M
    N Engl J Med; 2006 Jun; 354(24):2619-21. PubMed ID: 16775247
    [No Abstract]   [Full Text] [Related]  

  • 15. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
    Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
    Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
    Hirsch FR; Varella-Garcia M; Cappuzzo F
    Oncogene; 2009 Aug; 28 Suppl 1():S32-7. PubMed ID: 19680294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
    Lee K; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Res Treat; 2020 Jan; 52(1):292-300. PubMed ID: 31345011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.